Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with a solid tumour, brain/central nervous system tumour, or lymphoma that has continued to grow or spread despite standard treatment, or where no effective standard treatment exists.
• People who are under 21 years old at the time of joining; people aged 21 or older may be considered if a study leader approves their inclusion based on having a cancer type typically seen in children or teenagers.
• People who are already enrolled in a precision medicine programme (such as PROFYLE, ZERO, or a similar programme approved by the study leadership).
• People joining an early-phase (Phase I) part of the trial must have cancer that can be detected and measured, or at least detected, on scans or tests.
• People joining a later-phase (Phase II) part of the trial must have cancer that can be clearly measured on scans or tests.
• People whose general health and ability to carry out daily activities meets a minimum functional score, as assessed by their doctor using an age-appropriate scale (confirm with trial site for exact score requirements).
• People with a life expectancy of at least 6 weeks.
• People who have recovered from the side effects of any previous cancer treatments, and who have waited the required time since their last treatment before enrolling.
• People whose major organs (such as liver, kidneys, and bone marrow) are functioning at an adequate level.
• People who are able to attend scheduled follow-up appointments and manage any side effects as required by the trial.
• Females who could potentially become pregnant must have a negative pregnancy test result before joining.
• Males who are fertile must agree to use adequate contraception during the trial and for a period after treatment ends.
• People who are able to provide a signed and dated consent form (for children, a parent or guardian would typically do this — confirm with trial site).

Who may not be able to join:

• People with brain or central nervous system tumours that are causing active symptoms, where their neurological condition is unstable, or where increasing doses of steroid medication are needed to manage their brain condition. (Note: people who have been on a stable steroid dose for at least 7 days before starting the study drug may still be considered.)
• People with significant digestive system problems that could affect how oral medications are absorbed — such as severe nausea, vomiting, diarrhoea, ulcerative disease, or malabsorption conditions. (This applies only to trial groups where medication is taken by mouth.)
• People with serious, uncontrolled heart conditions, including a history of irregular heartbeats, unstable reduced blood flow to the heart, or heart failure within the past 12 months.
• People with a known active hepatitis virus infection, HIV infection, or any other infection that is not under control.
• People who have had major surgery within 21 days before the first dose of the trial drug. (Certain smaller procedures require only a 48-hour gap — confirm with trial site for specifics.)
• People who are known to have had a serious allergic reaction to any of the study drugs or their ingredients.
• People who are pregnant or currently breastfeeding.
• People with any other serious medical condition or organ problem that, in the treating doctor's judgement, could put the person at risk or affect the ability to assess the safety of the trial drugs.

Important: Always verify eligibility with the trial site directly before applying.